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Abstract In this experiment, we have investigated the
spatial memory performance of rats following a central
noradrenaline depletion induced by three different doses of
the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzyl-
amine (DSP4) and following administration of three dif-
ferent doses of methylphenidate (MPH). The rats were
required to find food pellets hidden on a holeboard. The
sole administration of DSP4 induced only minor cognitive
deficits. However, the treatment with MPH increased the
reference memory error, the impulsivity and the motor
activity of the DSP4-treated rats. Since the noradrenergic
terminals in a DSP4-treated rat are significantly reduced,
the administration of MPH has little effect on the norad-
renergic system and increases dopaminergic rather than
noradrenergic activity, resulting in an imbalance with rel-
atively high dopaminergic and low noradrenergic activities.
It is suggested that a reduction of noradrenaline and an
increase of dopamine induce ADHD-related deficits and
that the depletion of noradrenaline is not sufficient for an
appropriate rat model of ADHD.
Keywords Spatial memory  DSP4  Methylphenidate 
Animal model  Attention deficit hyperactivity disorder 
Rat
Introduction
The characteristic features of children and adolescents
with attention deficit hyperactivity disorder (ADHD) are
excessive motor activity, inattention and impulsiveness
(e.g. Lange et al. 2010; Tucha et al. 2008, 2009). The
treatment with psychostimulants such as methylphenidate is
the standard pharmacological therapy of ADHD (e.g. Lange
et al. 2007; Tucha et al. 2006a, b, c). Methylphenidate has
been shown to increase dopaminergic and noradrenergic
activity most likely by blocking noradrenaline and dopa-
mine transporters (Heal et al. 2009). These neurotransmit-
ters appear, therefore, to play an important role in ADHD.
However, it is not fully understood how an increase in
catecholaminergic activity ameliorates the symptoms of
ADHD. The degeneration of the locus coeruleus (LC),
which is the main source of noradrenaline in the central
nervous system, has been associated with deficits in atten-
tion and selective processing of sensory stimuli (Coull
1994). An increase in noradrenaline leads to a more focused
behaviour whereas a decrease in noradrenaline increases the
reaction to irrelevant stimuli (Aston-Jones et al. 1997).
These observations suggest that a decrease in central nor-
adrenaline might contribute to ADHD. Since there is a
similarity in symptoms between patients with ADHD and
those with prefrontal lesions (Benton 1991; Heilman et al.
1991; Levin 1938; Mattes 1980) it has been postulated that
the prefrontal cortex (PFC) is critically involved in ADHD.
This view is underlined by the fact that abnormalities within
the prefrontal cortex have been found in children with
ADHD (Castellanos et al. 1996; Filipek et al. 1997; Hynd
et al. 1990). The prevailing theory regarding the neurobi-
ology of ADHD suggests an imbalance of dopamine and
noradrenaline in the prefrontal cortex (Arnsten 2009, 2011;
Himelstein et al. 2000). In summary, these findings suggest
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that a reduction in noradrenaline can induce prefrontal
deficits which might contribute to ADHD.
In the present experiment, a depletion of central nor-
adrenaline was induced with the neurotoxin N-(2-chloro-
ethyl)-N-ethyl-2-bromobenzylamine (DSP4). This neurotoxin
is known to selectively destroy the terminals of the LC
(Fritschy and Grzanna 1991) and to reduce the noradren-
ergic activity in a dose-dependent manner (Cheetham et al.
1996). We have used different doses of DSP4 to induce
different imbalances between dopamine and noradrenaline
and expected to find behavioural deficits related to the
prefrontal cortex. In order to assess prefrontal functions
such as working memory, we have used a holeboard task
where rats are required to find hidden food pellets (Heim
et al. 2000). Different doses of methylphenidate (MPH)
were used in order to treat the expected deficits.
Materials and methods
Animals and feeding procedure
Forty-eight male Wistar rats aged about 3 months (weight
approximately 230 g at the beginning of the experiment)
were used. The animals were kept on a 12:12 h light–dark
cycle (room temperature 21C, humidity 55%). Water was
provided ad libitum.
All experiments were performed in accordance with the
national laws (German law on Protection of Animals) and
the principles of laboratory animal care (NIH publication
No. 86-23, revised 1985).
Training, DSP4 administration and test procedure
Prior to the administration of the neurotoxin DSP4, the rats
were trained once a day on the COGITAT System until
each rat had found the hidden pellets at least twice. This
training period lasted approximately 3 weeks. The animals
were trained in the morning and the order in which the rats
were trained on the board was balanced. When the animals
had reached this level, they were divided in four groups of
12 animals each. The rats in the four groups were matched
according to number of pellets eaten, working memory
error and reference memory error.
The animals of the control group were injected with
saline (DSP4_C); the animals of the other three groups
received an injection of DSP4 (Sigma-Aldrich, Schnelldorf,
Germany) at a dose of 10 mg/kg (DSP4_1), 20 mg/kg
(DSP4_2), or 50 mg/kg (DSP4_3). Both DSP4 and saline
were administered intraperitoneally. Following the injec-
tions, the animals were not tested for 2 weeks in order to
allow for a recovery of the peripheral noradrenergic system
(Fritschy and Grzanna 1991). The feeding of the animals
was kept constant during this period. The animals were then
tested again with the same pellet pattern on the COGITAT
System (10 trials per rat over 2 weeks). The rats were put on
starvation rations during the week prior to testing with the
COGITAT System and throughout the subsequent test
periods. The rats’ weight was carefully controlled and a
weight reduction of more than 10–15% was avoided in
order to prevent stress (Bear 1999; Deroche et al. 1995) and
subsequent changes in the dopaminergic system (Pothos
et al. 1995). The rats were fed 1 h prior to the start of
testing. This procedure was chosen for two reasons: (1) rats
awaiting their daily feeding after testing may not search
properly during the trials; (2) feeding shortly before testing
avoids the decrease in dopamine release associated with
chronic food deprivation (Pothos et al. 1995).
Injection of MPH
The effects of MPH were tested using three different doses
of the drug and saline as control (2.5, 5, 10 mg/kg). These
doses have been shown to improve attentional functions as
assessed with the 5-choice-serial-reaction-time task
(Bizarro et al. 2004). The injections were given 10 min
before the testing because the maximum concentration in
the brain can be measured within the first 20 min after
administration (Huff and Davies 2002). Each rat was tested
with saline and the three MPH doses. Saline and each MPH
dose were injected over five consecutive days. In order to
avoid carry-over effects, the order in which the rats were
injected was balanced using Latin squares. A wash-out
period of 3 days was used (Yang et al. 2003).
COGITAT Hole Board
The learning behaviour of the rats was tested with the
COGITAT Hole Board System (Cogitron GmbH, Go¨ttingen,
Germany). This system consists of a board with 25 holes
(Fig. 1). Each hole of the board is closed at its lower end by
an adjustable feeding plate with a depression for a food
pellet. Feeding plate and food pellets are of the same colour.
The ground below the feeding plate is covered with the same
pellets as those used in the cylindrical tubes, in order to
prevent the animals from finding the pattern of the pellet
distribution by using olfactory stimuli. Each hole is fitted
with infra-red light beams at different levels of the hole to
measure activity. Finally, there is an infra-red beam at the
feeding plate measuring the collection of a food pellet.
A more detailed description of the COGITAT Hole Board
System can be found elsewhere (Heim et al. 2000).
In the present experiment, eight of the 25 holes were
baited (Fig. 1). A search trial was automatically finished
when a rat had found all the hidden pellets or after a fixed
period of time (60 s).
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In each single trial, the following parameters were
measured: (1) working memory error (i.e. the percentage of
inspections to previously baited holes in a single trial in
relation to the total number of holes inspected); (2) refer-
ence memory error (i.e. the percentage of inspections to
non-baited holes in relation to the total number of holes
inspected); (3) pellets eaten (the number of pellets eaten);
(4) inspections (i.e. the number of interruptions of the
upper light beam only).
In addition, all trials were recorded with a video system.
This data was digitalised and analysed using the video
tracking system ETHOVISION 3.0 (Noldus, Wageningen,
The Netherlands). The parameter measured was the route
covered, i.e. the distance travelled by the rats (per trial,
in cm).
Statistics
Statistical analyses were performed using the non-para-
metric Wilcoxon-test, an alpha level of 0.05 was applied.
The analyses were performed using the Statistical Package
for Social Sciences 13.0 (SPSS) for Windows.
Results
In the following, the calculated values are given as
means ± standard error of the means.
Pellets eaten (Fig. 2)
Comparison between the DSP4 groups after saline
injection
The DSP4 groups differed in the saline condition, whereas
the DSP4_C group found significantly more pellets
compared to the DSP4_1 (7.74 ± 0.18 vs. 6.93 ± 0.59;
P B 0.01) and the DSP4_3 (7.74 ± 0.18 vs. 6.52 ± 0.69;
P B 0.01). The DSP4_2 group found more pellets than the
DSP4_1 group (7.52 ± 0.31 vs. 6.93 ± 0.59; P B 0.05)
and the DSP4_3 group (7.52 ± 0.31 vs. 6.52 ± 0.69;
P B 0.05).
Treatment with MPH in the DSP4_C group
The treatment of the rats in the DSP4_C group with MPH
at a dose of 2.5 mg/kg induced a small but significant
increase in pellets found in comparison with the saline
injection (saline vs. MPH 2.5 mg: 7.74 ± 0.18 vs. 7.93 ±
0.09; P B 0.05). Treating this group with 10 mg/kg of
MPH decreased the number of pellets eaten compared to
the treatment with 2.5 mg MPH (MPH 2.5 mg vs. MPH
10 mg: 7.93 ± 0.09 vs. 7.53 ± 0.33; P B 0.05).
Treatment with MPH in the DSP4_1 group
(10 mg/kg DSP4)
The treatment of the DSP4_1 group with MPH had no
statistically significant effects on the number of pellets
eaten in comparison with the saline injection.
Treatment with MPH in the DSP4_2 group
(20 mg/kg DSP4)
The treatment of the DSP4_2 group with the high dose of
MPH (10 mg/kg) resulted in a significant decrease in the
number of pellets eaten in comparison with the saline
injection (saline vs. MPH 10 mg: 7.52 ± 0.31 vs. 5.82 ±
0.90; P B 0.01). The treatment with 2.5 mg/kg of MPH
also induced a reduction in the number of pellets eaten
(saline vs. MPH 2.5 mg: 7.52 ± 0.31 vs. 6.46 ± 0.70;
P B 0.05).
Fig. 1 Schematic drawing of the COGITAT system
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Fig. 2 Number of pellets eaten (error bars indicate SEM)
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Treatment with MPH in the DSP4_3 group
(50 mg/kg DSP4)
The treatment of the DSP_3 group with 5 mg/kg of MPH
induced a significant decrease in the number of pellets
eaten in comparison with the saline injection (saline vs.
MPH 5 mg: 6.52 ± 0.69 vs. 4.67 ± 0.95; P B 0.01). The
low dose of MPH also reduced this number (saline vs.
MPH 2.5 mg: 6.52 ± 0.69 vs. 5.41 ± 0.86; P B 0.05).
The high dose of MPH had no statistically significant effect
on the number of pellets eaten.
Working memory error (Fig. 3)
Comparison between the DSP4 groups after saline
injection
There were no significant differences between the groups.
However, the highest dose of DSP4 induced an increase in
the working memory error.
Treatment with MPH in the DSP4_C group
No significant differences between the three doses of MPH
and saline injection were found.
Treatment with MPH in the DSP4_1 group
(10 mg/kg DSP4)
No significant differences between the three doses of MPH
and saline injection were found.
Treatment with MPH in the DSP4_2 group
(20 mg/kg DSP4)
A significant difference was found between the doses of 2.5
and 5 mg/kg of MPH (MPH 2.5 mg vs. MPH 5 mg:
13.95 ± 7. vs. 26.81 ± 10.43; P B 0.05). No other sig-
nificant differences were found.
Treatment with MPH in the DSP4_3 group
(50 mg/kg DSP4)
No significant differences between the three doses of MPH
and saline injection were found.
Inspections (Fig. 4)
Comparison between the DSP4 groups after saline
injection
There are no significant differences.
Treatment with MPH in the DSP4_C group
MPH at a dose of 2.5 or 5 mg/kg had no significant effect
on the number of inspections compared to saline. However,
the dose of 10 mg/kg significantly increased the inspection
rate compared to saline (saline vs. MPH 10 mg: 1.81 ±
1.56 vs. 6.10 ± 3.16; P B 0.01).
Treatment with MPH in the DSP4_1 group
(10 mg/kg DSP4)
The treatment with MPH increased the number of
inspections in this group in a dose-dependent manner.
In comparison to the saline injection, the increase
in inspections was significant for the MPH doses of
2.5 mg/kg (saline vs. MPH 2.5 mg: 1.25 ± 0.54 vs.
5.45 ± 2.20; P B 0.01), 5 mg/kg (saline vs. MPH 5 mg:
1.25 ± 0.54 vs. 6.13 ± 2.02; P B 0.01) and 10 mg/kg
(saline vs. MPH 10 mg: 1.25 ± 0.54 vs. 8.02 ± 2.81;
P B 0.01).
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Treatment with MPH in the DSP4_2 group
(20 mg/kg DSP4)
The treatment with all three doses of MPH significantly
increased the number of inspections compared to the saline
injection: with 2.5 mg/kg (saline vs. MPH 2.5 mg: 1.83 ±
0.81 vs. 4.66 ± 1.68; P B 0.05), with 5 mg/kg (saline vs.
MPH 5 mg: 1.83 ± 0.81 vs. 5.54 ± 2.54; P B 0.05) and
with 10 mg/kg (saline vs. MPH 10 mg: 1.83 ± 0.81 vs.
8.36 ± 2.54; P B 0.05).
Treatment with MPH in the DSP4_3 group
(50 mg/kg DSP4)
The treatment with all three doses of MPH significantly
increased the number of inspections compared to the saline
injection: (saline vs. MPH 2.5 mg: 2.13 ± 1.36 vs. 6.47 ±
1.73; P B 0.01), (saline vs. MPH 5 mg: 2.13 ± 1.36 vs.
7.52 ± 1.82; P B 0.01) and (saline vs. MPH 10 mg:
2.13 ± 1.36 vs. 9.17 ± 2.52; P B 0.01).
Reference memory error (Fig. 5)
Comparison between the DSP4 groups after saline
injection
The treatment with saline did not have any effect on this
parameter in the DSP4 treated groups.
Treatment with MPH in the DSP4_C group
The treatment with 10 mg/kg of MPH induced a significant
increase in the reference memory error compared to
saline injection (saline vs. MPH 10 mg: 15.98 ± 9.55 vs.
38.42 ± 11.43; P B 0.01) and to the dose of 2.5 mg/kg of
MPH (MPH 2.5 mg vs. MPH 10 mg: 22.85 ± 10.80 vs.
38.42 ± 11.43; P B 0.05).
Treatment with MPH in the DSP4_1 group
(10 mg/kg DSP4)
The treatment with 10 mg/kg of MPH induced a significant
increase in the reference memory error compared to saline
injection (saline vs. MPH 10 mg: 18.56 ± 10.08 vs.
31.83 ± 10.36; P B 0.05).
Treatment with MPH in the DSP4_2 group
(20 mg/kg DSP4)
The treatment of the DSP4_2 group with MPH at doses of
2.5 and 10 mg/kg increased the reference memory error
compared to the saline injection (saline vs. MPH 2.5 mg:
16.62 ± 8.55 vs. 29.98 ± 9.80; P B 0.05), (saline vs.
MPH 10 mg: 16.62 ± 8.55 vs. 27.42 ± 8.82; P B 0.05).
Treatment with MPH in the DSP4_3 group
(50 mg/kg DSP4)
The treatment with all three doses of MPH significantly
increased the reference memory error compared to the
saline injection (saline vs. MPH 2.5 mg: 17.45 ± 10.07 vs.
41.37 ± 9.65; P B 0.01), (saline vs. MPH 5 mg: 17.45 ±
10.07 vs. 38.83 ± 7.44; p B 0.01), (saline vs. MPH 10 mg:
17.45 ± 10.07 vs. 43.97 ± 8.78; P B 0.01).
Route covered (Fig. 6)
Comparison between the DSP4 groups after saline
injection
There was no significant difference between the groups.
Treatment with MPH in the DSP4_C group
The high dose of MPH induced an increase in the route
covered (saline vs. MPH 10 mg: 193.75 ± 55.93 vs.
320.84 ± 92.62; P B 0.01).
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Treatment with MPH in the DSP4_1 group
(10 mg/kg DSP4)
All MPH doses increased the route covered in comparison
with the saline injection (saline vs. MPH 2.5 mg: 193.50 ±
55.86 vs. 328.57 ± 94.85; P B 0.01), (saline vs. MPH
5 mg: 193.50 ± 55.86 vs. 364.05 ± 105.09; P B 0.01),
(saline vs. MPH 10 mg: 193.50 ± 55.86 vs. 416.56 ±
120.25; P B 0.01).
Treatment with MPH in the DSP4_2 group
(20 mg/kg DSP4)
All MPH doses increased the route covered in comparison
with the saline injection (saline vs. MPH 2.5 mg: 205.87 ±
59.43 vs. 320.41 ± 92.50; P B 0.01), (saline vs. MPH
5 mg: 205.87 ± 59.43 vs. 368.54 ± 106.39; P B 0.05),
(saline vs. MPH 10 mg: 205.87 ± 59.43 vs. 445.87 ±
128.71; P B 0.01).
Treatment with MPH in the DSP4_3 group
(50 mg/kg DSP4)
All MPH doses increased the route covered in comparison
with the saline injection (saline vs. MPH 2.5 mg: 187.17 ±
54.03 vs. 367.36 ± 106.05; P B 0.01), (saline vs. MPH
5 mg: 187.17 ± 54.03 vs. 482.40 ± 139.26; P B 0.01),
(saline vs. MPH 10 mg: 187.17 ± 54.03 vs. 490.70 ±
141.65; P B 0.01).
Discussion
The present experiment was performed in order to inves-
tigate the effects of noradrenaline depletion on cognition in
rats and the administration of MPH. Given the role of the
LC in the regulation of attention processes, we expected to
find impaired cognition due to the administration of DSP4.
The animal groups treated with three different doses of
DSP4 differed significantly in the number of pellets eaten.
The rats treated with the low and the high doses of DSP4 ate
the lowest number of pellets compared to the saline group
(Fig. 2). Similar differences were also observed in our
previous experiment (Sontag et al. 2008) indicating cogni-
tive difficulties in the DSP4-treated rats. The LC neurons
project, among others, to the prefrontal cortex and show two
distinct firing modes, i.e. (1) tonic firing which is associated
with arousal, sensory information processing, attention,
working memory and motor processes (Arnsten and Dudley
2005; Aston-Jones et al. 1994; Devilbiss and Waterhouse
2004; Foote et al. 1980, 1983) and (2) phasic discharge
which is associated with alerting and orienting reactions,
sustained attention and decision-making (Aston-Jones
et al. 1994; Clayton et al. 2004). We therefore expected to
find deficits in working memory. With increasing doses of
DSP4 a non-significant increase in working memory error
was found (Fig. 3). No increase was found for the reference
memory error (Fig. 5). This suggests that DSP4 induces
deficits in working memory rather than in reference
memory.
The administration of MPH induced only minor effects.
There was a small but significant increase in the number of
pellets eaten following the administration of 2.5 mg/kg
MPH. The working memory error decreased, though not
significantly, following treatment with 2.5 mg/kg of MPH,
indicating an improvement in cognition. However, with
increasing doses both the reference and the working mem-
ory error increased, suggesting a decline in cognitive
functions (Figs. 3, 5) An impairment of working memory
with increasing doses of MPH was also reported by Dev-
ilbiss and Berridge (2008) who showed that MPH at a dose
of 2.0 mg/kg induces severe deficits in working memory
whereas a dose below 2.0 mg/kg enhances working mem-
ory in naı¨ve rats. It was also reported that the administration
of 2.5 mg/kg MPH induced a significant increase in motor
activity (Gaytan et al. 1997) and the use of small MPH
doses was suggested by Arnsten and Dudley (2005) in order
to avoid the stimulating effects on motor activity. However,
the rats in the present study did not walk longer distances
after 2.5 or 5 mg/kg of MPH (Fig. 6). Only the high dose of
MPH increased the distances walked by the rats. The effect
on working memory was minor compared to the data pre-
sented by Devilbiss and Berridge (2008). Both Devilbiss
and Berridge (2008) and Gaytan et al. (1997) used Sprague–
Dawley rats whereas we used Wistar rats. The present
results may therefore suggest a reduced sensitivity to the
effects of MPH in Wistar rats. Furthermore, it can be
excluded that the alterations in cognitive functions found in
the DSP4-C group after the injection of 2.5 or 5 mg/kg
MPH are related to an increase in motor activity.
The pre-treatment with DSP4 appears to potentiate the
effects of MPH. The treatment of the DSP4_3 group with
2.5 mg/kg MPH significantly increased the reference
memory error which did not further increase with higher
doses of MPH. This finding suggests a ceiling effect
(Fig. 5). The increase in reference memory error was
associated with a decrease in the number of pellets eaten
(Fig. 2). These findings indicate a deficit in spatial memory
induced by MPH. This is underlined by the fact that the rats
travelled significantly longer distances during the testing
(Fig. 6). The dose of 2.5 mg/kg MPH had no such effects on
the DSP4-C group, on the contrary, this dose slightly
increased the cognition in the rats. An increase in the ref-
erence memory error, a decrease in the pellets eaten, and an
increase in the distance travelled were, though less pro-
nounced, also observed in the DSP4_2 group (Figs. 2, 5, 6).
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By contrast, the DSP4_1 group showed only a significant
increase in the reference memory error after the high dose of
MPH (Fig. 5). These findings suggest that the pre-treatment
with different doses of DSP4 induced different sensitivities
to MPH, leading to deficits in spatial reference memory.
It was expected that MPH would reduce working
memory deficits in DSP4-treated rats. Since MPH increases
noradrenaline release, it was also expected that this effect
would be more pronounced in the groups treated with the
low doses of DSP4 because more noradrenergic LC ter-
minals would survive this treatment (Cheetham et al.
1996). However, no significant effects of MPH on working
memory compared to saline were found in any of the
DSP4-treated groups. The effects of MPH and DSP4 on
reference memory and the lack of effects on working
memory suggest that the MPH and DSP4 might have
affected brain structures outside the prefrontal cortex, most
likely the hippocampus.
Both prefrontal cortex and hippocampus receive inner-
vations from the LC (Foote et al. 1983). The administration
of DSP4 may therefore have depleted noradrenaline in both
brain regions. For the hippocampus, Chrobak et al. (1985)
reported a significant decrease of noradrenaline but no
effect on dopamine following the administration of DSP4
in rats. This study also showed that the administration of
DSP4 did not affect spatial memory. Another study has
shown that a decrease in dopamine disturbs spatial learning
(Gasbarri et al. 1996). MPH increases both dopamine and
noradrenaline release. In DSP4-treated rats, however, nor-
adrenaline release is markedly reduced since DSP4
destroys the noradrenergic terminals. One would therefore
expect that MPH increased dopamine release in the hip-
pocampus. This reasoning is in contrast to the finding that a
decrease in hippocampal dopamine disturbs spatial learn-
ing (Gasbarri et al. 1996).
Another possibility is that the increase in reference
memory error in DSP4-treated rats after MPH administra-
tion is related to an increase in motor activity. We found no
stimulation of motor behaviour in saline-treated rats but in
all DSP4 pre-treated rats MPH induced a significant
increase in motor activity (Fig. 6) Furthermore, MPH also
increased the number of inspections, indicating an increase
in impulsive behaviour (Fig. 4). This suggests that a
reduction of noradrenaline in combination with an increase
in dopamine induce motor hyperactivity and impulsivity,
two core symptoms of ADHD.
In summary, central noradrenaline depletion following
DSP4 administration induced cognitive deficits without
affecting reference memory. The treatment with MPH
affected reference memory rather than working memory.
In addition, there were indications that MPH also increased
impulsivity and motor activity of the DSP4-treated rats,
which are two core symptoms of ADHD. Since the
noradrenergic terminals in a DSP4-treated rat are signifi-
cantly reduced, the administration of MPH increases
dopaminergic activity rather than noradrenergic activity.
These results therefore suggest that a reduction of nor-
adrenaline and an increase of dopamine may induce
ADHD-related deficits. The sole depletion of noradrenaline
is therefore not sufficient for an appropriate rat model of
ADHD (see Sontag et al. 2010).
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